Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Societal costs associated to chronic thromboembolic pulmonary hypertension : A study utilizing linked national registries

Kjellström, Barbro LU ; Runheim, Hannes ; Beaudet, Amélie ; Husberg, Magnus ; Ivarsson, Bodil LU ; Pillai, Nadia ; Levin, Lars Åke and Bernfort, Lars (2023) In Pulmonary Circulation 13(2).
Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but serious complication after a pulmonary embolism. Healthcare resource utilization (HCRU; hospitalization, outpatient visits, and drug utilization) as well as productivity loss (sick leave and disability pension) before and after the CTEPH diagnosis is sparsely studied. By linking several Swedish national databases, this study estimated the societal costs in a national CTEPH cohort (n = 369, diagnosed with CTEPH in 2008−2019) 5 years before and 5 years after diagnosis (index date) and compared to an age, sex, and geographically matched control group (n = 1845, 1:5 match). HCRU and productivity loss were estimated per patient per year. Patients were stratified as operated... (More)

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but serious complication after a pulmonary embolism. Healthcare resource utilization (HCRU; hospitalization, outpatient visits, and drug utilization) as well as productivity loss (sick leave and disability pension) before and after the CTEPH diagnosis is sparsely studied. By linking several Swedish national databases, this study estimated the societal costs in a national CTEPH cohort (n = 369, diagnosed with CTEPH in 2008−2019) 5 years before and 5 years after diagnosis (index date) and compared to an age, sex, and geographically matched control group (n = 1845, 1:5 match). HCRU and productivity loss were estimated per patient per year. Patients were stratified as operated with pulmonary endarterectomy (PEA group) or not operated (non-PEA group). Direct and indirect societal costs were 2.1 times higher before, and 8.1 times higher after the index date for patients with CTEPH compared to the matched control groups. The higher costs were evident already several years preceding the index date. The main cost driver before the index date in both the PEA and the non-PEA groups was productivity loss. The productivity loss remained high for both groups in the 5-year period following the index date, but the main cost drivers were prescribed drugs and hospitalizations for patients that underwent PEA and prescribed drugs in the non-PEA group. In conclusion, CTEPH was associated with large societal costs related to healthcare consumption and productivity loss, both before and after diagnosis.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
burden of disease, burden of illness, mortality, national registry, pulmonary embolism
in
Pulmonary Circulation
volume
13
issue
2
article number
e12254
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:37362560
  • scopus:85162713569
ISSN
2045-8932
DOI
10.1002/pul2.12254
language
English
LU publication?
yes
id
8a64fa9c-43ca-4b66-82bd-5f9364afb207
date added to LUP
2023-09-19 11:05:07
date last changed
2025-05-04 17:14:27
@article{8a64fa9c-43ca-4b66-82bd-5f9364afb207,
  abstract     = {{<p>Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but serious complication after a pulmonary embolism. Healthcare resource utilization (HCRU; hospitalization, outpatient visits, and drug utilization) as well as productivity loss (sick leave and disability pension) before and after the CTEPH diagnosis is sparsely studied. By linking several Swedish national databases, this study estimated the societal costs in a national CTEPH cohort (n = 369, diagnosed with CTEPH in 2008−2019) 5 years before and 5 years after diagnosis (index date) and compared to an age, sex, and geographically matched control group (n = 1845, 1:5 match). HCRU and productivity loss were estimated per patient per year. Patients were stratified as operated with pulmonary endarterectomy (PEA group) or not operated (non-PEA group). Direct and indirect societal costs were 2.1 times higher before, and 8.1 times higher after the index date for patients with CTEPH compared to the matched control groups. The higher costs were evident already several years preceding the index date. The main cost driver before the index date in both the PEA and the non-PEA groups was productivity loss. The productivity loss remained high for both groups in the 5-year period following the index date, but the main cost drivers were prescribed drugs and hospitalizations for patients that underwent PEA and prescribed drugs in the non-PEA group. In conclusion, CTEPH was associated with large societal costs related to healthcare consumption and productivity loss, both before and after diagnosis.</p>}},
  author       = {{Kjellström, Barbro and Runheim, Hannes and Beaudet, Amélie and Husberg, Magnus and Ivarsson, Bodil and Pillai, Nadia and Levin, Lars Åke and Bernfort, Lars}},
  issn         = {{2045-8932}},
  keywords     = {{burden of disease; burden of illness; mortality; national registry; pulmonary embolism}},
  language     = {{eng}},
  number       = {{2}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Pulmonary Circulation}},
  title        = {{Societal costs associated to chronic thromboembolic pulmonary hypertension : A study utilizing linked national registries}},
  url          = {{http://dx.doi.org/10.1002/pul2.12254}},
  doi          = {{10.1002/pul2.12254}},
  volume       = {{13}},
  year         = {{2023}},
}